Hyperion Defi, Inc.

Hyperion DeFi maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.97, indicating adequate short-term liquidity coverage. The balance sheet holds $70.1 million in total assets against $11.6 million in liabilities, resulting in $58.5 million in total equity. Cash and equivalents stand at $7.4 million, providing a buffer against operating cash outflows. However, the company trades at a price-to-book ratio of 0.79, reflecting a market valuation below its tangible book value. The absence of long-term debt reduces fixed financial obligations, but the reliance on equity financing introduces dilution risks.

Profitability metrics present a complex picture driven by non-operating gains. The company reported a net income of $8.8 million for Q1 2026, primarily fueled by $10.9 million in unrealized gains on digital assets and $3.6 million in realized gains. Operating income was $8.7 million, despite operating expenses of $4.8 million in selling, general, and administrative costs and $0.3 million in research and development. Return on equity is negative at -0.77, and return on assets is -0.65, indicating that the core business operations have not yet generated sustainable returns on invested capital. The high operating leverage is evident in the gross profit of $244,271, which is entirely offset by operating expenses before the inclusion of digital asset gains.

Revenue concentration is split between the Ophthalmic Technology segment and the Digital Assets segment. The Ophthalmic Technology segment generates revenue through licensing agreements, such as those with Bausch and Formosa Pharmaceuticals. The Digital Assets segment contributes through trading activities and revenue-sharing agreements involving tokens like HYPE and Hyperlend. The company’s geographic exposure is primarily domestic, with significant operations in the United States, including New York. The reliance on digital asset valuations introduces volatility into the revenue mix, as seen in the significant unrealized gains reported in Q1 2026.

Growth trajectory shows a sharp increase in revenue from $14,720 in Q1 2025 to $244,271 in Q1 2026, a year-over-year increase of over 1,500%. This growth is largely attributable to the expansion of digital asset activities and new revenue-sharing agreements. However, the company has a history of net losses, with a net loss of $3.5 million in Q1 2025. The transition from loss to profit in Q1 2026 is driven by non-recurring digital asset gains rather than organic growth in core pharmaceutical operations. The company has also seen significant increases in shares outstanding, from 2.18 million in Q1 2025 to 11.43 million in Q1 2026, reflecting aggressive equity financing.

Risk factors include high dilution risk, as evidenced by the diluted share count being materially above the basic share count. The company has an active At-the-Market (ATM) offering program, which allows for continuous equity issuance. Additionally, the company holds significant digital assets, including HYPE tokens and liquid staking tokens, which are subject to high market volatility. The company also faces regulatory risks associated with digital asset operations and potential changes in cryptocurrency regulations. The reliance on a few key licensing agreements for the ophthalmic segment introduces concentration risk.

Recent events include the filing of an 8-K report indicating material changes, and the company has been active in equity financing through ATM offerings and warrant inducements. The company has also entered into new revenue-sharing agreements and asset use service agreements related to its digital asset holdings. The Q1 2026 filing highlights the company’s strategic shift towards digital assets, with significant unrealized gains impacting the bottom line. The company has also issued preferred stock dividends, which are paid in kind, further contributing to share dilution.

Hyperion Defi, Inc. (HYPD) has recorded its first notable holder change, marking a new entry in its ownership structure. As of June 30, 2024, investor ID 466 added 124,799 shares to their position, representing a portfolio weight of approximately 0.000168% and a value of $0.074 million. This activity was detected on June 20, 2026, and stands as the primary material signal for the ticker, given that this is the first analysis for HYPD with no prior basis for delta computation. The significance of this addition lies in the context of Hyperion Defi’s current corporate profile. The company currently reports zero officers and zero analyst coverage, indicating a lack of public-facing executive leadership or professional market scrutiny at this time. Furthermore, HYPD holds no index memberships, suggesting it remains outside major market benchmarks and likely has limited visibility among institutional index funds. Despite the absence of analyst coverage and index inclusion, the company maintains a shareholder base comprising nine top holders. The entry of investor ID 466 adds to this group, though the specific identity of the investor is not disclosed in the available data. The relatively small value of the transaction underscores the micro-cap nature of the security, where even modest share counts can represent notable changes in ownership concentration. This initial data point establishes a baseline for future monitoring of Hyperion Defi, Inc. With no prior history of holder changes to compare against, this addition serves as the first reference point for tracking investor interest. The lack of accompanying cross-source signals or saga events suggests that this holder change is an isolated corporate action rather than part of a broader strategic shift or market event. Future analyses will depend on whether this activity is followed by additional institutional interest or changes in the company’s operational structure.

Analysts project 79% upside to a mean price target of $6.28, signaling strong institutional confidence in future valuation.

Revenue grew at a 289.1% CAGR from FY2023 to FY2025, demonstrating significant top-line expansion momentum over the period.

The company maintains a zero debt-to-equity ratio, placing it in the top quartile for leverage safety within its cohort.

A current ratio of 2.68 indicates strong short-term liquidity, providing a buffer against immediate operational cash flow pressures.

Liquidity risk is assessed as low, suggesting the company can meet its short-term obligations without significant distress.

The company faces high dilution risk, which threatens existing shareholder value and could significantly reduce earnings per share.

Operating margin of -57.4% places the company in the bottom quartile of the pharmaceutical cohort, indicating severe inefficiency.

Revenue $244.3k; Operating income $8.7M.

• ▍Revenue $244.3k
• ▍Operating income $8.7M
• ▍Net margin 3619.2%

Revenue $317.2k; Operating income -$7.0M.

• ▍Revenue $317.2k
• ▍Operating income -$7.0M
• ▍Net margin -1749.2%

Revenue $14.7k; Operating income -$11.4M.

• ▍Revenue $14.7k
• ▍Operating income -$11.4M
• ▍Net margin -82706.9%

Revenue $813.5k; Operating income -$46.7M.

• ▍Revenue $813.5k
• ▍Operating income -$46.7M
• ▍Net margin -5570.6%

Revenue $57.3k; Operating income -$48.7M.

• ▍Revenue $57.3k
• ▍Operating income -$48.7M
• ▍Net margin -86888.6%

Revenue $57.3k; Operating income -$48.7M.

• ▍Revenue $57.3k
• ▍Operating income -$48.7M
• ▍Net margin -86888.6%

Revenue $3.8k; Operating income -$25.4M.

• ▍Revenue $3.8k
• ▍Operating income -$25.4M
• ▍Net margin -719859.9%

Revenue $3.8k; Operating income -$25.4M.

• ▍Revenue $3.8k
• ▍Operating income -$25.4M
• ▍Net margin -719859.9%